Advanced Enzyme Technologies Share Price

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes. The Company was incorporated, as a Private Company on March 15, 1989 as Advanced Biochemicals Private Limited in Maharashtra. It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005.In 2011, the company took over CalIndia Foods International, giving the company direct presence in USA.In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA.Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders. The IPO was open for subscription during the period from 20 July 2016 to 22 July 2016. The said offer was overall subscribed 82.06 times. The equity shares of Advanced Enzyme Technologies Limited were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 1 August 2016 at an opening market price of Rs 1,210 on both the exchanges compared with the IPO price of Rs 896 per share.During the financial year ended 31 March 2017, Advanced Enzyme Technologies Limited acquired 1.43 crore equity shares at Rs 35 per share of JC Biotech Private Limited (JCB), aggregating to Rs 50.08 crore, 70% of the paidup share capital of JCB. In view of this JCB became subsidiary with effect from December 1, 2016.The subdivision of equity shares of the company from face value of 10 each to face value of 2 each (Stock Split) and consequent alteration in Capital Clause of Memorandum of Association of was approved by the companys shareholders on May 04, 2017, through a Postal Ballot. The Record Date for the purpose of ascertaining the shareholders entitled to receive the said subdivided equity shares was fixed by the Board as May 26, 2017. Subsequently, the company issued five (5) subdivided equity shares of 2 each in lieu of one (1) equity share of 10 each to the eligible shareholders of the company.On 3 July 2017, Advanced Enzyme Technologies completed the acquisition of 200,000 equity shares of MYR 1 (Malaysia Ringgit) each aggregating to MYR 200,000 (equivalent to approx. 3,134,000) of AEM i.e. 80% of paidup share capital of AEM. The company also subscribed to right issue of 150,000 Equity Shares at MYR 1 per share of AEM, aggregating to MYR 150,000 (equivalent to 2,602,500) on 13 March 2018. On 20 March 2018, the company completed the acquisition of remaining stake i.e. 50,000 equity shares of face value of MYR 1 each of AEM. The said acquisition was made at face value for a total consideration of MYR 50,000 (equivalent to 867,800). In view of the above, AEM has become a whollyowned subsidiary of the company, effective from March 30, 2018.The companys wholly owned subsidiary, Advanced Enzymes Europe BV acquired 100% stake in evoxx technologies GmbH (evoxx) and evoxx became a stepdown subsidiary of the Company in 202021. In January 2021, it completed the acquisition of controlling stake of 51% in SciTech Specialities Private Limited (SSPL), India, a contract manufacturing company specializing in effervescent granules and tablets with 2 manufacturing facilities and 1 RD unit, which became a subsidiary of Company effective from January 11, 2021. On 29 May 2021, Company acquired additional stake of 15% from existing shareholders of JC Biotech Private Limited (JCB) at a consideration of Rs. 211.25 Million. The said acquisition by increase in stake in JCB was completed on August 18, 2021 and the stake of Company in JCB increased from existing 70% to 85%. In 2023, the Company acquired an additional stake of 4.83% in subsidiary, JC Biotech, resulting in a total stake of 89.83%. It acquired 50% stake in Saiganesh Enzytech Solutions Private Limited on 03 January 2023 and it became a subsidiary of the Company. The Company launched Wellfa, a B2C consumer brand and further introduced new products including enzymes for producing chiral/ nonchiral molecules Pepzyme Pro, clinically proven product for optimizing protein digestion, uptake, and gut modulation SacchariSEB ML for easily absorbable dietary fiber production and Code T400, designed to enhance tea properties.Further, the Company acquired additional stake of 5.89% in its subsidiary JC Biotech Private Limited effective on March 5, 2024 and post the additional acquisition, the Company holds 95.72% stake in the subsidiary.The Company subsidiary Starya Labs Inc, established an independent facility for testing services of enzymes and probiotic product in the US market in FY 2025.

Advanced Enzyme Technologies reported a Q1 FY 2025-26 revenue of ₹185.91 crore, up 1.4% YoY, with net profit decreased -2.2% to ₹40.44 crore. For the full year FY2025–2026, revenue reached ₹669.95 crore and profit touched at ₹133.97 crore. As of Jun '25, Advanced Enzyme Technologies’s market capitalisation stood at ₹3,804.52 crores. Shareholding as of Jun '25 shows promoters holding 43.1%, with FIIs at 23.4%, DIIs at 8.5%, and public at 25%.

As of 17 Sep, 2025, Advanced Enzyme Technologies share price is ₹340. The stock opened at ₹344.8 and had closed at ₹345.2 the previous day. During today’s trading session, Advanced Enzyme Technologies share price moved between ₹339.25 and ₹348.30, with an average price for the day of ₹343.77. Over the last 52 weeks, the stock has recorded a low of ₹257.90 and a high of ₹571.00. In terms of performance, Advanced Enzyme Technologies share price has increased by 27.4% over the past six months and has declined by 34.18% over the last year.